Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375791 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
A Phase 2 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00375791: Completed Phase 2 study, sponsored by AEterna Zentaris.
NCT00375791 is a Phase 2 study that has completed, run by AEterna Zentaris. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00375791, a Phase 2 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
Primary Outcome
To determine the response rate (the combined Complete Response (CR) + Partial Response (PR) + Minor Response (MR) following treatment with perifosine in patients with multiple myeloma who have relapsed following Initial front-line therapy and are refractory to their most recent therapy.
Interventions
- DRUG dexamethasone
- DRUG perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00375791 record still lists
NCT00375791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00375791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00375791 about?
NCT00375791 is a clinical study titled "Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma". This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
What is the current status of trial NCT00375791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2005-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00375791?
The interventions under investigation include: dexamethasone (DRUG), perifosine (DRUG).
Who is sponsoring clinical trial NCT00375791?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00375791's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia